Back to homepage

Tag "empagliflozin"

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond

Authors: Elif A Oral

This paper summarizes the results from the ground-breaking EMPA-REG OUTCOME study and discusses their significance and clinical implications.

More

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin

Authors: Andrew Ahmann

Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of antidiabetes agents with an insulin-independent mechanism of action, making them suitable for use in combination with any other class of antidiabetes agents, including insulin. In this review the evaluates a 78-week, randomized, double-blind, placebo controlled trial investigating the impact of empagliflozin, an SGLT2 inhibitor, as add-on to basal insulin in patients with inadequate glycemic control on basal insulin, with or without metformin and/or a sulfonylurea.

More

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents

Authors: Eva M Vivian

Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce complications. This article reviews the evidence from clinical trials and suggests that SGLT2 inhibitors are a promising new treatment option for T2DM.

More

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

Authors: Joshua J Neumiller

Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options.

Unlike previously available agents, sodium-glucose co-transporter 2 inhibitors offer an insulin-independent mechanism for improving blood glucose levels, since they promote urinary glucose excretion by inhibiting glucose reabsorption in the kidney.

In this article, the author discusses empagliflozin and based on available data, it appears that this drug may be a useful option in a range of patients; however, clinical decisions will be better informed by the results of ongoing studies, in particular, a large cardiovascular outcome study (EMPA-REG OUTCOME™).

More